FDA extends Casgevy approval to children aged two and older

Wider label, same delivery bottleneck

The FDA extended Casgevy's approval on 1 July 2026 to patients aged two and older. The minimum age fell from 12. The label now covers sickle cell disease with recurrent vaso-occlusive crises and transfusion-dependent beta-thalassemia. Dr. Megha Kaushal, acting deputy director of the FDA's Office of Therapeutic Products, said the decision rested on evidence that earlier treatment reduces the risk of lasting organ damage. "Making this therapy available to younger patients opens a critical window for intervention," she said.

Casgevy, or exagamglogene autotemcel, remains the first and only CRISPR-based medicine authorized for human use anywhere, according to the FDA. Vertex Pharmaceuticals developed it with CRISPR Therapeutics. The agency said the approval adds roughly 5,500 American children to the eligible group.

Thin pediatric data

Alana J. Arnold, chief executive of PEMPal, said the pediatric data set behind the expansion was thin. It covered 11 patients, eight of them evaluable, and showed 12 consecutive months without a vaso-occlusive episode. "The data set that they used was pretty thin," Arnold said. She warned that a two-year-old's burden of disease differs from that of a 40-year-old's.

Uptake is tiny

Through the first quarter of 2026, more than 500 of the roughly 60,000 eligible patients worldwide had started Casgevy, MMM reported. That is fewer than 1% of that eligible group. The FDA first approved Casgevy in December 2023, more than two years earlier. Patient initiations nearly tripled year over year, according to a Simply Wall St analysis published on Yahoo Finance. The same analysis put reimbursement at about 90% of eligible US patients.

The full course takes about 12 months from start to finish, MMM reported. National Geographic reported that because each treatment is manufactured from a patient's own cells, even experienced hospitals can treat only a handful of people each year. More than 50 qualified treatment centers have passed the manufacturers' checks, and they cluster in major cities and academic medical hubs.

Where families enter care

Arnold said 85% of children who pass through an emergency room nationally are treated at community facilities, not children's hospitals, because families go to whichever ER is closest when a child is in pain. Clinicians most likely to see those patients first are often unaware Casgevy exists, she said. The list price is $2.2 million per patient, MMM reported.

National Geographic described Ian Wilhite, a patient who needed a full-time caregiver and faced weeks away from employment and months of restricted activity during treatment. He lost 30 pounds in the month he spent in the hospital. His parents drove from Austin, Texas, to the University of Kansas Medical Center and took shifts at his bedside. Mark Walters, director of the blood and marrow transplantation program at UCSF Benioff Children's Hospital Oakland, told the magazine the biggest chokepoint is societal. The need is an engaged, resourced family, he said. Most of the 100,000 Americans living with sickle cell disease do not have those conditions, National Geographic reported.

How the therapy works

MMM reported that Casgevy does not repair the sickle mutation. It edits BCL11A so that infused stem cells produce fetal hemoglobin. Patients receive chemotherapy first to clear space in the bone marrow. The edited cells are infused as a one-time procedure.

What remains unknown

Arnold said outcomes data for Casgevy at the youngest end of the new approval window does not yet exist. She also cited Pfizer's withdrawal of Oxbryta nearly two years earlier, which she linked to more vaso-occlusive episodes and higher death rates. "We have to be very prudent and be eyes-wide-open about this fantastic advancement," she said.